1月7日，万邦德盘中下跌2.07%，截至10:21，报13.74元/股，成交6541.53万元，换手率0.85%，总市值 84.05亿元。 资金流向方面，主力资金净流出862.65万元，特大单买入217.10万元，占比3.32%，卖出918.92万元，占 比14.05%；大单买入1380.43万元，占比21.10%，卖出1541.26万元，占比23.56%。 万邦德今年以来股价跌1.36%，近5个交易日涨0.88%，近20日涨10.18%，近60日跌4.58%。 资料显示，万邦德医药控股集团股份有限公司位于浙江省台州市温岭市城东街道百丈北路28号，成立日 期1999年3月31日，上市日期2006年11月20日，公司主营业务涉及铝加工产品、医疗器械产品的生产与 销售;现代中药、化学原料药及化学制剂的研发、生产和销售业务。主营业务收入构成为：医疗器械 41.63%，化学原料药及制剂24.69%，其他商品19.61%，中药14.07%。 万邦德所属申万行业为：医药生物-中药Ⅱ-中药Ⅲ。所属概念板块包括：小盘、医疗器械、一带一路、 有色铝、增持回购等。 截至9月30日，万邦德股东户数2.64万，较上期减少32.75% ...

Company Overview - Angli康 is a pharmaceutical company based in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1][2]. Financial Performance - For the period from January to September 2025, Angli康 reported a revenue of 1.055 billion yuan, a year-on-year decrease of 5.92%. However, the net profit attributable to shareholders increased by 55.59% to 77.6899 million yuan [2]. - The company has distributed a total of 360 million yuan in dividends since its A-share listing, with 128 million yuan distributed over the past three years [3]. Stock Performance - As of November 26, Angli康's stock price increased by 2.04% to 40.60 yuan per share, with a total market capitalization of 8.19 billion yuan. The stock has risen by 213.25% year-to-date, although it has seen a decline of 0.55% over the last five trading days [1]. - The stock has appeared on the "龙虎榜" (a trading board for stocks with significant trading activity) 15 times this year, with the most recent appearance on October 21, where it recorded a net buy of 15.2289 million yuan [1]. Shareholder Structure - As of September 30, 2025, Angli康 had 28,500 shareholders, an increase of 54.58% from the previous period. The average number of circulating shares per shareholder decreased by 35.31% to 6,493 shares [2]. - Notable institutional shareholders include 广发医疗保健股票A, 中欧医疗健康混合A, and several new entrants such as 汇添富创新医药混合A and 长城医药产业精选混合发起式A [3]. Industry Classification - Angli康 operates within the pharmaceutical and biotechnology sector, specifically in the chemical pharmaceutical and chemical formulation sub-industry. The company is associated with various concepts, including ursodeoxycholic acid, Helicobacter pylori, pet economy, hypertension prevention, and vitamins [2].

Group 1 - The core viewpoint of the news is that Anglikang's stock price increased by 5.09%, reaching 44.81 CNY per share, with a trading volume of 1.038 billion CNY and a turnover rate of 12.93%, resulting in a total market capitalization of 9.039 billion CNY [1] - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001. It was listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikang's main business includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, others at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of fund holdings, one fund under AVIC Fund has a significant position in Anglikang. The fund "AVIC Preferred Navigation Mixed Initiation A" (022852) held 396,100 shares in the third quarter, accounting for 3.4% of the fund's net value, ranking as the tenth largest holding [2] - The "AVIC Preferred Navigation Mixed Initiation A" fund was established on December 24, 2024, with a latest scale of 60.61 million CNY. It has achieved a return of 73.81% this year, ranking 222 out of 8147 in its category [2] - The fund manager, Wang Sen, has been in position for 2 years and 48 days, managing total assets of 2.85 billion CNY. During his tenure, the best fund return was 136.74%, while the worst was 2.83% [2]

Group 1 - The core point of the news is that Anglikang's stock price increased by 5.09%, reaching 44.81 CNY per share, with a trading volume of 1.039 billion CNY and a turnover rate of 12.94%, resulting in a total market capitalization of 9.039 billion CNY [1] - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001. The company was listed on October 23, 2018, and its main business involves the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikang's main business includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, other products at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of major fund holdings, one fund under Tongtai Fund has a significant position in Anglikang. The Tongtai Health Theme Mixed A Fund (011002) held 66,200 shares in the third quarter, accounting for 4.99% of the fund's net value, making it the sixth-largest holding [2] - The Tongtai Health Theme Mixed A Fund (011002) was established on April 8, 2021, with a latest scale of 13.7512 million CNY. Year-to-date, it has achieved a return of 21.89%, ranking 4112 out of 8147 in its category; over the past year, it has returned 9.34%, ranking 5366 out of 8056; since inception, it has incurred a loss of 49.99% [2] Group 3 - The fund managers of Tongtai Health Theme Mixed A Fund (011002) are Ma Yi and Mai Jianpei. As of the report, Ma Yi has a cumulative tenure of 11 years and 241 days, with a total fund asset size of 2.718 billion CNY, achieving a best fund return of 45.64% and a worst return of -0.63% during his tenure [3] - Mai Jianpei has a cumulative tenure of 185 days, with a total fund asset size of 231 million CNY, achieving a best fund return of 21.48% and a worst return of -1.56% during his tenure [3]

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and listed on October 23, 2018. The company is engaged in the research, production, and sales of chemical raw materials and preparations [1] - The main business revenue composition includes preparations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Stock Performance - As of November 12, Anglikang's stock price increased by 2.02%, reaching 43.50 CNY per share, with a total market capitalization of 8.775 billion CNY [1] - Year-to-date, Anglikang's stock price has risen by 233.13%, with an 8.42% increase over the last five trading days and a 5.58% increase over the last 20 days, while it has decreased by 17.97% over the last 60 days [1] Financial Performance - For the period from January to September 2025, Anglikang reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while the net profit attributable to shareholders was 77.6899 million CNY, reflecting a year-on-year increase of 55.59% [2] - The company has distributed a total of 341 million CNY in dividends since its A-share listing, with 108 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Anglikang had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which holds 3.3384 million shares, and several new entrants among the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the news is that Angli康's stock price increased by 5.02%, reaching 43.55 yuan per share, with a trading volume of 1.197 billion yuan and a turnover rate of 15.44%, resulting in a total market capitalization of 8.785 billion yuan [1] - Angli康 is primarily engaged in the research, production, and sales of chemical raw materials and formulations, with its main business revenue composition being: formulations 43.46%, raw materials 39.82%, specialty intermediates 12.44%, others 3.72%, and pharmaceutical excipients 0.56% [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Shenwan Lixin has a significant holding in Angli康. The Shenwan Lixin Medical Pioneer Stock A (005433) reduced its holdings by 54,900 shares in the third quarter, holding 212,100 shares, which accounts for 6.17% of the fund's net value, ranking as the fourth largest heavy stock [2] - The Shenwan Lixin Medical Pioneer Stock A (005433) has a current scale of 1.11 billion yuan and has experienced a loss of 10.27% this year, ranking 4213 out of 4216 in its category; over the past year, it has lost 17.54%, ranking 3921 out of 3922; since its inception, it has lost 51.68% [2] Group 3 - The fund manager of Shenwan Lixin Medical Pioneer Stock A (005433) is Yao Hongfu, who has been in the position for 3 years and 117 days, with the total asset scale of the fund being 1.31 billion yuan. The best fund return during his tenure is -36.17%, while the worst return is -37.16% [3]

Core Insights - The stock price of Anglikon increased by 2.07% on November 11, reaching 42.33 CNY per share, with a total market capitalization of 8.539 billion CNY [1] - Year-to-date, Anglikon’s stock has risen by 224.17%, with a recent 3.67% increase over the last five trading days [1] - For the first nine months of 2025, Anglikon reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while net profit attributable to shareholders increased by 55.59% to 77.6899 million CNY [2] Financial Performance - Anglikon has been listed on the stock market since October 23, 2018, and has a primary business focus on the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikon includes 43.46% from formulations, 39.82% from raw materials, 12.44% from specialty intermediates, 3.72% from others, and 0.56% from pharmaceutical excipients [1] - Cumulative cash dividends since the A-share listing amount to 341 million CNY, with 108 million CNY distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, Anglikon had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which increased its holdings by 95,050 shares, and new entrants such as Huatai-PineBridge Innovation Medical Mixed A [3]

Group 1 - The core point of the news is that Anglikon experienced a decline of 5.14% in its stock price, reaching 38.73 yuan per share, with a trading volume of 711 million yuan and a turnover rate of 9.47%, resulting in a total market capitalization of 7.813 billion yuan [1] - Anglikon Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001, with its listing date on October 23, 2018. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main business revenue composition of Anglikon includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, others at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of major fund holdings, Invesco Great Wall Fund has a significant position in Anglikon, with its Invesco Great Wall Medical Industry Stock A (022081) increasing its holdings by 72,000 shares in the third quarter, totaling 120,000 shares, which accounts for 5.98% of the fund's net value, ranking as the ninth largest holding [2] - The Invesco Great Wall Medical Industry Stock A (022081) was established on January 24, 2025, with a latest scale of 31.4463 million. Since its inception, it has achieved a return of 36.99% [2] - The fund manager, Qiao Haiying, has a tenure of 11 years and 58 days, with the total asset scale of the fund being 1.182 billion yuan. The best fund return during her tenure is 147.43%, while the worst return is -12.35% [2]

Core Viewpoint - The stock of Anglikang has experienced significant fluctuations, with a year-to-date increase of 202.50% but a recent decline of 11.87% over the past five trading days, indicating volatility in investor sentiment and market performance [1]. Company Overview - Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and went public on October 23, 2018. The company is located in Shengzhou, Zhejiang Province, and specializes in the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition of Anglikang includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), other products (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported an operating income of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% compared to the previous year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders of Anglikang increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, Guangfa Technology Innovation Mixed A, and others, indicating increased institutional interest in the company [3].

Core Viewpoint - The stock of Anglikang has shown significant volatility, with a year-to-date increase of 192.23%, but recent declines in the short term raise questions about future performance [1][2]. Company Overview - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, established on December 30, 2001, and listed on October 23, 2018. The company focuses on the research, production, and sales of chemical raw materials and formulations [1]. - The main revenue composition includes formulations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1]. Financial Performance - For the first half of 2025, Anglikang reported operating revenue of 724 million yuan, a year-on-year decrease of 14.52%, and a net profit attributable to shareholders of 65.93 million yuan, down 3.19% year-on-year [2]. - Since its A-share listing, Anglikang has distributed a total of 341 million yuan in dividends, with 108 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 50.49% to 18,500, with an average of 10,037 circulating shares per person, a decrease of 33.55% [2]. - Notable new institutional shareholders include China Europe Medical Health Mixed A, holding 6.44 million shares, and Guangfa Technology Innovation Mixed A, holding 6.16 million shares [3].